Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) 是从大肠杆菌 (E. coli O127:B8) 中提取的脂多糖和TLR-4激活剂,其特征为S型LPS。它具有典型的三部分结构:O抗原、R3核心寡糖和脂质A。该化合物通过激活免疫细胞的TLR-4,引起炎症反应和回肠收缩力,常用于构建肠道炎症模型。
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML).